Black Women with HIV at Highest Risk for Premature Mortality a 21-year Study Finds
IDWeek 2021: Despite declining mortality rates among patients with HIV in the past 2 decades, a new study finds significant disparities in gender and race.
People Living with HIV Use Fewer Essential Clinical Services and Less Frequently During Pandemic
Viral-load monitoring rates decreased and clinic visits declined overall despite an increase in use of telehealth.
CDI-specific Follow-up Visits Rare among Patients Hospitalized for Recurrence
IDWeek 2021: A new study found that only 16% of patients with CDI rehospitalized for recurrent infection had been seen in follow-up 30 days after original discharge.
Health Care Workers Likely to Recommend COVID-19 Vaccine to Patients Based on Safety Messaging, Survey Finds
Survey authors said findings merit further research into how to increase health care workers' confidence in discussing and recommending COVID-19 vaccines with patients.
Obesity May Put Children Hospitalized with COVID-19 at Higher Risk for Severe Disease, Suggests New Study
IDWeek 2021: Obesity prevention and vaccination efforts may help prevent COVID-19-related morbidity in pediatric COVID-19 patients with obesity, noted authors of a new study.
IDWeek 2021: C diff Clinical Outcomes Unchanged after 2017 IDSA Guideline Update
IDWeek 2021: Use of vancomycin vs metronidazole increased after the 2017 IDSA recommendation but CDI recurrence rates increased slightly, investigators report.
HCV Cure is Possible in Young Drug Users, Suggests New Research Being Presented at IDWeek 2021
IDWeek 2021: Young people who inject drugs can be cured of hepatitis C virus infection, according to 2 new studies.
Remdesivir May Significantly Reduce Risk of Hospitalization in High-risk COVID-19 Patients, Suggests New Study
Findings from a phase 3 clinical trial showed remdesivir reduced the risk of COVID-19-related hospitalizations by 87% in high-risk patients, the drug's manufacturer announced.
At ADA 2021, John Buse, MD, PhD, says US Must Focus on Control of Obesity, Other T2D Risk Factors
Diabetes investigator John Buse, MD, PhD, says laser focus on reducing T2D risk factors is equally as important as using the next right drug against the disease.
Inside GRADE: Exec Committee Member John Buse, MD, PhD, Toplines Study Results, Calls for More Head-to-Head Research
Dr Buse’s in-depth review of the GRADE study is followed by a discussion of the keen need for more comparative research and the many new questions the results have raised about optimal T2D therapy.
ADA 2021: Baseline Insulin Use May not Impact Benefits of Finerenone in Patients with CKD, T2D
ADA 2021. A subgroup analysis of the FIDELIO-DKD trial showed that finerenone use was beneficial regardless of baseline insulin use among patients with T2D and CKD.
GLP-1 RA, Insulin More Effective Second-line vs Sulfonylurea, DPP-4 Inhibitor for T2D
Preliminary GRADE study results showed that liraglutide and insulin glargine added to metformin maintained A1c level in target range longer than glimepiride or sitagliptin.
ADA 2021: Use of Dapagliflozin Decreases Risk of Diabetes in Patients with CKD
ADA 2021. Dapagliflozin was found to reduce type 2 diabetes incidence among patients with chronic kidney disease in a prespecified analysis of the DAPA-CKD trial.
ADA 2021: Renoprotection with Finerenone Consistent Regardless of SGLT2 Inhibitor Use
ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not SGLT2 inhibitors were on board at study baseline.
ADA 2021: Study Finds Hospitalization Rates for New-onset Pediatric T2D Doubled During Pandemic
Data released today at the American Diabetes Association 81st Scientific Sessions on a spike in new onset pediatric T2D at a single center during COVID-19 may signal much wider incidence.
ADA 2021 Symposia Focus on Health Disparities Exposed and Deepened by COVID-19 Pandemic
Leading international diabetes researchers and clinicians will use the ADA's 81st annual Scientific Sessions as an ideal classroom to examine pandemic impact on diverse populations with diabetes.
ADA Virtual Meeting Will Offer 5 Symposia on Latest COVID-19 Findings
The upcoming ADA virtual 81st Scientific Sessions will feature 5 sessions on the latest diabetes developments learned during the initial phases of the COVID-19 pandemic.
Clinical Trial Updates at the ADA Scientific Sessions 2021: A few primary care musts
The American Diabetes Association 2021 Scientific Sessions run from June 25 to 29. This short slide show highlights 6 clinical trial updates that are a "must see" for primary care clinicians.
ACC.21: High- and Low-Dose Aspirin Both Effective for Patients with Established Cardiovascular Disease
ACC.21: There was no difference found between high- and low-dose aspirin in terms of effectiveness and safety in patients with established CVD, according to new research.
ACC.21: Survival After MI Far Worse for Black Patients from Disadvantaged Neighborhoods
ACC.21: Black patients from disadvantaged neighborhoods were found almost 20% more likely to die within 5 years of MI than white patients from well-resourced ones in a new study.
